Diamond-Blackfan anemia is a congenital erythroid hypoplasia and is associated with physical malformations and predisposition to cancer. Twenty-five percent of patients have mutations in gene encoding ribosomal protein S19 (RPS19). Through overexpression of ribosomal protein S19 using a lentiviral vector with the spleen focus-forming virus promoter, we demonstrated that Diamond-Blackfan anemia phenotype can be successfully treated in Rps19 deficient mice. In our present study we assessed efficacy of a clinically relevant promoter, the human elongation factor 1α short promoter, with or without Locus control region of β-globin gene for treatment of ribosomal protein S19 -deficient Diamond-Blackfan anemia. The findings demonstrate, these vectors rescue the proliferation defect and improve erythroid development of transduced RPS19 deficient bone marrow cells. Remarkably, bone marrow failure and severe anemia in Rps19-deficient mice was cured with enforced expression of ribosomal protein S19 driven by elongation factor 1α short promoter. We also demonstrate that ribosomal protein S19 -deficient bone marrow cells can be transduced and these cells had the capacity to repopulate bone marrow in long-term reconstituted mice. Our results collectively demonstrate the feasibility to cure ribosomal protein S19 -deficient Diamond-Blackfan anemia using lentiviral vectors with cellular promoters that possess reduce risk of insertional mutagenesis.
Introduction
Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure disorder with pure red blood cell aplasia manifesting early in life. The hematological profile of DBA patients shows macrocytic anemia with reticulocytopenia, normal or decreased levels of neutrophils and variable platelets counts 1 . DBA patients also exhibit various non hematological manifestations such as physical abnormalities and cancer predisposition 2, 3. In at least 60-70% of cases, DBA is caused by functional haploinsufficiency of genes encoding for ribosomal proteins 4, 5, 6, 7, 8, 9, 10, 11. Recent studies have discovered two novel genes, erythroid transcriptional factor GATA1 and TSR2, a direct binding partner of RPS26, can cause the DBA phenotype 35, 36, 37. Twenty-five percent of the patients have mutations in a gene coding ribosomal protein S19 (RPS19) 4 . For given mutations all reported patients are heterozygous. Furthermore, in most of the cases the mutations are predicted to result in haploinsufficiency of the respective ribosomal protein 12, 13. Corticosteroids are the main therapeutic option in DBA 3. Around 80% of the patients initially respond to corticosteroids, but only 40% of patients sustain the therapeutic response and the remaining 40% of patients need chronic blood transfusion. Twenty percent of the patients go into spontaneous remission and uphold acceptable hemoglobin level without therapeutic intervention. The only curative treatment available for DBA patients is allogeneic bone marrow transplantation 14. Our previous studies demonstrated that enforced expression of RPS19 improves the proliferation, erythroid colony-forming potential and differentiation of patient derived RPS19-deficient hematopoietic progenitor cells in vitro 15, 16. Moreover, RPS19
overexpression enhances the engraftment and erythroid differentiation of patient-derived hematopoietic stem and progenitor cells when transplanted into immune-compromised mice 17 . Collectively these studies suggest that gene therapy may be a future therapeutic modality 4 in the treatment of RPS19-deficient DBA. In our proof of principle study, using lentiviral vectors harbouring the spleen focus-forming virus (SFFV) promoter a codon-optimized human RPS19 cDNA followed by IRES and GFP (SFFV-RPS19), we showed that the DBA phenotype of the of the Rps19-deficient mice can be successfully treated
18.
In our current study, we are assessing the efficacy of clinically relevant promoters to drive the therapeutic gene. To this effect, we designed lentiviral vectors harboring a codon-optimized human RPS19 cDNA driven by the shortened version of human elongation factor 1α (EFS)
promoter. Lentiviral vectors with EFS promoter have been shown to have a significantly decreased risk of insertional mutagenesis 27, 33 and no evidence of clonal dominance were reported during clinical trials of gene therapy for SCID-X1 using EFS promoter 34.
The EFS promoter is followed by IRES and GFP (EFS-RPS19), while a vector without the RPS19 cDNA was used as a control (EFS-Spacer). To assess the therapeutic potential of the EFS-RPS19 vector in vivo, we transduced c-Kit enriched bone marrow cells from control and uninduced shRNA-D mice were injected into lethally irradiated wild-type mice. The recipients transplanted with the EFS-Spacer transduced shRNA-D bone marrow showed a dramatic decrease in blood cellularity that led to death after a few weeks, while the recipients transduced with EFS-RPS19 shRNA-D bone marrow exhibited close to normal blood cellularity. These results demonstrate that the EFS promoter driven enforced expression of RPS19 can cure the severe anemia and bone marrow failure in RPS19 deficient mice.
Results
Enforced expression of RPS19 by the EFS promoter in Rps19 deficient bone marrow cells improves proliferation and erythroid development in vitro. 5 We have shown that enforced expression of RPS19 expands the erythroid development in RPS19-deficient DBA patients 15, 16, 17. In our previous study using lentiviral vectors driven by SFFV promoter, we showed that the DBA phenotype of the mice can be successfully treated 18 . In this study we assessed the efficacy of clinically relevant promoters like the EFS promoter in our mouse model of RPS19 deficient DBA. Concisely, this model contains an Rps19-targeting shRNA (shRNA-D) that is expressed under a doxycycline-responsive promoter located downstream of the Collagen A1 gene ( Figure 1A ). Experimental animals were bred to be either heterozygous (D+) or homozygous (DD) for the shRNA in order to generate two models with intermediate or severe Rps19 deficiency, respectively ( Figure 1B ).
To correct the Rps19 deficiency, we developed Self Inactivating (SIN) -lentiviral vectors harboring a codon-optimized human RPS19 cDNA driven by the internal EFS promoter, followed by IRES and GFP (EFS-RPS19) with or without a beta-globin locus control region (LCR) cassette ( Figure 1C ). The codon-optimized RPS19 cDNA was further modified to prevent its recognition and downregulation by the Rps19-targeting shRNA used. A similar vector without the RPS19 cDNA was used as a control vector (EFS-Spacer) 18 , 20, 21, 22.
In order to assess the functionality of these vectors, we cultured transduced c-Kit enriched BM cells from control and heterozygous RPS19 shRNA (D+) mice in liquid cultures in the presence of doxycycline ( Figure 2A ). Based on the percentage of GFP+ cells initial transduction efficiency were found to be on average between 20% and 40% ( Figure 3C ). The D+ cells transduced with the EFS-Spacer control vector failed to expand during 7 days of culture after transduction ( Figure 2B ). In contrast, the EFS-RPS19 and LCR-EFS-RPS19
vectors mediated a 2-fold increase in total cell number when compared to the EFS-Spacer vector.
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Next we quantified the erythroid colony forming potential of transduced c-Kit enriched BM cells from control and D+ mice in methyl cellulose cultures in the presence of doxycycline for 14 days (Figure 2 C ). The findings demonstrate that the EFS-RPS19 and LCR-EFS-RPS19 vectors mediated a 3-fold increase in total number of erythroid colonies when compared to the EFS-Spacer vector. Following engraftment and stable donor derived regeneration of the hematopoietic system, the recipient mice were administered doxycycline to downregulate the endogenous Rps19 in order to induce the disease ( Figure 3A ). Since we have shown previously that the hematopoietic phenotype in Rps19-deficient mice is autonomous to the blood system, we decided to use lethally irradiated wild-type recipients 22.
Before transplantation, initial transduction efficiencies with therapeutic and control vectors were measured based on the percentage of GFP+ cells and found to be on average between 20% and 40% ( Figure 3C ). After two weeks of doxycycline treatment most of the mice 7 receiving DD bone marrow transduced with EFS-Spacer vector died due to dramatic bone marrow failure (data not shown). At this time point all groups showed high overall donor reconstitution confirming the absence of recipient-derived hematopoiesis ( Figure 3D ). We demonstrated that the recipients transplanted with the EFS-RPS19 or LCR-EFS-RPS19 DD bone marrow had normal blood cellularity ( Figure 3E-F) .
Doxycycline administration for 18 weeks was used as time point to assess long term efficacy ( Figure 4A ). Most recipients with the DD bone marrow transduced with EFS-spacer vectors died but the remaining surviving recipients exhibited a decrease in erythrocyte numbers, hemoglobin value, platelet counts and showed macrocytic anemia ( Figure 4B -H).
Remarkably, the recipients transplanted with the EFS-RPS19 or LCR-EFS-RPS19 DD bone marrow had normal blood cellularity and bone marrow cellularity ( Figure 4C -H).
Additionally, we analyzed the samples by FACS to allow fractionation of the myeloid - Supplementary Figures 1-3 . We did not observe a tendency to preferentially integrate within a 10 kb window around the TSS of genes ( Figure 7A ). The overlap of EFS-RP19 insertions with the retroviral tagged cancer gene database (RTCGD) 38 or the All Onco cancer gene list 39 was not different from a randomized control dataset ( Figure 7B ). We did not observe a significant difference in the clonal diversity between the vector groups. However, six mice had a lower sequence diversity (Supplementary Figure 2f) Table 2 ) and for all detected CIS (Supplementary Table 3) . A chi-square analysis revealed no statistical differences for the overlap with cancer gene databases between the vector groups. When we check for common high risk insertions in or near Prdm16, Mecom, Notch1, Lmo2, Setbp1, Ccnd2, Sox4, Tal1, we either found no hits (Lmo2, Tal1) or only read contributions ≤ 0.58% (n=19 out of 5420 sequences).
Discussion
In this study we demonstrate the efficacy of RPS19 lentiviral vectors using clinically relevant promoters to correct the lethal bone marrow failure in Rps19 deficient mice. We showed that the EFS promoter can express enough RPS19 to correct RPS19 deficient bone marrow failure and here for EFS driven RPS19 single gene vector can be used in a clinical gene therapy trial for RPS19 deficient DBA. Previously we already demonstrated that enforced expression of RPS19 improves the proliferation, erythroid colony-forming potential and differentiation of patient derived RPS19-deficient hematopoietic progenitor cells in vitro 15, 16 . Using xenograft models we have also shown that overexpression of RPS19 enhances the engraftment and erythroid differentiation of patient-derived hematopoietic stem and progenitor cells 17. In our proof of principle study, using lentiviral vectors driven by the SFFV promoter, harboring a codon-optimized human RPS19 cDNA followed by IRES and GFP, we showed that the DBA phenotype of the mice can be successfully treated
In the current study we decided to utilize ubiquitously expressed EFS promoter with or Remarkably, the bone marrow failure generated by DD bone marrow was cured with EFS-RPS19. Since quite high levels of RPS19 are needed to correct the RPS19 deficiency by transgenesis, we were concerned that the EFS promoter might not generate sufficient levels of RPS19 in erythroid progenitors to correct the anemia. Therefore, we included vectors containing the EFS plus the beta globin locus control region. However, the findings show that the EFS promoter without the beta globin locus control region generates sufficient levels of RPS19 to cure the anemia and bone marrow failure in RPS19 deficient mice.
Additionally, we demonstrated that RPS19-deficient bone marrow cells can be transduced and these cells survived the transduction procedure and had the capacity to repopulate the bone marrow. However, most of the studies were performed with transduced shRNAD/D 11 bone marrow and transplanted into normal recipients. The RPS19 deficiency was induced once the recipients had a stable graft. This is a justified since we have previously shown that the anemia and bone marrow failure in the induced mice is due to the deficiency in the It is of course clear that the RPS19 vectors can only be used to treat patients with RPS19 deficient DBA. Therefore, patients with mutations in other ribosomal protein genes or the GATA1 gene cannot be treated with RPS19 vectors. Recently, mutations in GATA1 were found in a few patients with DBA. The GATA1 gene in humans produces two mRNAs, a long one and a short one. The DBA patients could not produce the long form of GATA1 35. Mice produce only the short form of GATA1 and it will therefore be difficult to evaluate the possibility of developing GATA1 gene therapy for GATA1 deficient DBA patients using mice as experimental animals.
The data presented in Figure 5 shows that the RPS19 vectors increase the production of HSC Rps19 deficiency, respectively. RPS19 deficiency was induced by feeding the mice with doxycycline in the drinking water (1 mg/ml or 2 mg/ml doxycycline; Sigma-Aldrich) supplemented with 10 mg/ml sucrose (Sigma-Aldrich). Mice were maintained at Lund
University animal facility and all animal experiments were performed with consent from Lund University animal ethics committee.
Blood and bone marrow analysis
Peripheral blood was collected from the tail vein into microvette tubes (Sarstedt) and analyzed using sysmex XE-5000. Erythrocytes were lysed using Ammonium chloride for 10 
Cell culture
C-Kit+ expressing cells were enriched using CD117 microbeads and MACS separation column (Miltenyi) and Retronectin-coated 20ng/ml; Takara) pre -stimulated in serum-free StemSpan®SFEM medium supplemented with P/S, mSCF (100ng/ml), hTPO (50ng/ml) in 6-well plates (non-tissue culture treated; BD) for 1 day 0.5*10 6 cells per ml. 12 well plates were preloaded with the viral vectors (50 ul per well corresponding to MOI of 10-20) and 0.5*10 6 cells were seeded into each well in 1 ml cultured in serum-free StemSpan®SFEM medium supplemented with P/S, mSCF (100ng/ml), murine IL3 (mIL3; 10 ng/ml; PeproTech), Erythropoietin (EPO; 2U/ml; Janssen-Cilag) with or without Doxycycline (1ug/ml). Light microscope was used to evaluate the proliferation of culture after 6 days. For BFU-E assay, 40*10 3 c-Kit+ transduced cells were seeded in 1.5ml of M3436 methylcellulose (StemCell Technologies) with doxycycline (1ug/ml) and colonies were scored on Day 14.
Insertion site analysis
We used 300 ng genomic DNA of whole bone marrow cells, isolated 18 weeks after 
GTGGGTTTTCCAGTCACACTGCTCTTCCGATCTTCCCTCAGACCCTTTTAGTCA-3')
and reverse primer recognizing the linker cassette (IT-IS-RV-PCR1: 5'-TTCGTTGGGAGTGAATTAGCC AGTGGCACAGCAGTTAGG-3'). The vector and linker specific sequences are underlined, the italic sequence represents a tail homologous to the primers used for Ion Torrent sequencing, as described previously 30 . Bioinformatics processing with custom Perl, R and visual basic scripts involved barcode primer assignment, trimming, clustering, filtering and MAVRIC alignment 31. For common insertion site (CIS) analysis, we followed the suggestions by Wu et al., considering only 5 or more insertions in a 50kb window 32. The distance to the transcriptional start sites was analyzed using the information of the MAVRIC alignments in combination with a customized R script (ggplot2;
geom_histogram with parameters aes y = density and binwidth 1000).
Control datasets for integration site analysis
The 
Statistical analysis
One-way ANOVA with Tukey's multiple-comparison test was used to determine statistical significance using GraphPad Prism Version 6 (GraphPad software). The genes of the top 10 contributing sequences (in %) are shown for each animal. The bar graphs on the right display this composition as stacked frequencies. The color code of the bars corresponds to the color code of the numbers (#) in the respective tables (grey indicate the sum of all other sequences). Gene symbols are colored in case they were found more than once. 
